Literature DB >> 11785715

Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study.

A Viscido1, V Bagnardi, G C Sturniolo, V Annese, G Frieri, A D'Arienzo, C Papi, G Riegler, G Corrao, R Caprilli.   

Abstract

BACKGROUND: Death rate for patients with ulcerative colitis has changed over last few decades. Recent studies indicate that cumulative long-term mortality is comparable to that in general population, and that deaths may depend on causes not strictly related to colonic disease. AIM: To evaluate overall and cause-specific mortality rate in a large group of Italian patients with ulcerative colitis.
METHODS: A total of 2,066 ulcerative colitis patients aged >18 years consecutively diagnosed in twenty Italian Gastroenterology Units between 1964 and 1995 were followed-up from diagnosis until 1997. Standardised Mortality Ratios and Relative Survival Ratios were calculated.
RESULTS: Overall mortality of patients with ulcerative colitis was comparable to that in general population with 93 deaths observed versus 92.1 expected (standardises mortality ratio, 1.0; 95% confidence interval, 0.8-1.2). Significantly higher mortality was observed in patients under 30 years of age at diagnosis (standardised mortality ratio, 2.7; 95% confidence interval, 1.3-4.9), and in those diagnosed before 1974 (standardised mortality ratio, 2.7; 95% confidence interval, 1.1-5.7). Proctocolitis and complications from surgery were mentioned in 11 and 5 certificates, respectively. A significant excess of deaths was observed for colorectal cancer (colon: standardised mortality ratio, 3.0; 95% confidence interval, 1.0-6.9; rectum: standardised mortality ratio, 4.4; 95% confidence interval, 1.2-11.3), and haemolymphopoietic neoplasms (standardised mortality ratio, 2.8; 95% confidence interval, 1.0-6.1), in particular multiple myeloma and non-Hodgkin lymphoma. A significant deficit of deaths was observed for cancer of the respiratory system (standardised mortality ratio, 0.3; 95% confidence interval, 0.1-1.0).
CONCLUSIONS: This study confirms that, also in Italy, mortality of patients with ulcerative colitis is comparable to that in general population. Only 12% of deaths were due to ulcerative colitis itself, whereas 10% of deaths were attributed to colorectal cancer. Deaths from colorectal cancer occurred, on average, 9 years after diagnosis of ulcerative colitis, suggesting that the risk of cancer is not limited to patients with long-standing colitis. As to mortality for causes unrelated to colitis, there was an excess of deaths due to malignancies of the haemolymphopoietic system.

Entities:  

Mesh:

Year:  2001        PMID: 11785715     DOI: 10.1016/s1590-8658(01)80046-3

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  17 in total

1.  MicroRNAs as Therapeutic Targets in Colitis and Colitis-Associated Cancer: Tiny Players With a Giant Impact.

Authors:  Ajay Goel
Journal:  Gastroenterology       Date:  2015-08-24       Impact factor: 22.682

Review 2.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

3.  Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer.

Authors:  Ziad Kanaan; Shesh N Rai; M Robert Eichenberger; Christopher Barnes; Amy M Dworkin; Clayton Weller; Eric Cohen; Henry Roberts; Bobby Keskey; Robert E Petras; Nigel P S Crawford; Susan Galandiuk
Journal:  Hum Mutat       Date:  2012-03       Impact factor: 4.878

Review 4.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

5.  Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004.

Authors:  T Jess; E V Loftus; W S Harmsen; A R Zinsmeister; W J Tremaine; L J Melton; P Munkholm; W J Sandborn
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

6.  Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.

Authors:  Angelica Nocerino; Alexandra Feathers; Elena Ivanina; Laura Durbin; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

7.  Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.

Authors:  Meenakshi Bewtra; Lisa M Kaiser; Tom TenHave; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

8.  Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001.

Authors:  G Masala; S Bagnoli; M Ceroti; C Saieva; G Trallori; I Zanna; G D'Albasio; D Palli
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

9.  Aggressive plasmablastic multiple myeloma in a 42-year-old: is inflammatory bowel disease or infliximab treatment to be blamed?

Authors:  Siddhartha Yadav; Ramesh Kumar; Ishmael A Jaiyesimi; Mohammad Muhsin Chisti
Journal:  BMJ Case Rep       Date:  2013-10-29

10.  Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.

Authors:  Caroline B Appleyard; Myrella L Cruz; Angel A Isidro; Janelle C Arthur; Christian Jobin; Claudio De Simone
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-09-08       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.